(NASDAQ: MGX) Metagenomi's forecast annual revenue growth rate of -18.24% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.74%.
Metagenomi's revenue in 2025 is $30,913,000.On average, 5 Wall Street analysts forecast MGX's revenue for 2026 to be $834,063,527, with the lowest MGX revenue forecast at $596,092,219, and the highest MGX revenue forecast at $1,379,843,099. On average, 4 Wall Street analysts forecast MGX's revenue for 2027 to be $907,317,238, with the lowest MGX revenue forecast at $617,343,680, and the highest MGX revenue forecast at $1,379,843,099.
In 2028, MGX is forecast to generate $538,270,222 in revenue, with the lowest revenue forecast at $308,671,840 and the highest revenue forecast at $788,481,771.